Literature DB >> 18089617

CD30 supports lung inflammation.

Sang-Yun Nam1, Young-Hyun Kim, Jeong-Su Do, Yun-Hwa Choi, Hyo-Jung Seo, Ho-Keun Yi, Pyung-Han Hwang, Chang-Ho Song, Hern-Ku Lee, Jeong-Su Kim, Eckhard R Podack.   

Abstract

The physiological functions of CD30 have not been fully elucidated. Here we show that in CD30-deficient mice (CD30(-/-)), lung inflammation is significantly diminished in the ovalbumin (OVA) model of airway hyperreactivity. In CD30(-/-) mice, the recruitment of eosinophils into the airways after OVA-aerosol challenge of OVA-primed mice was significantly diminished when compared with wild-type (w.t.) mice. IL-13 levels were also significantly reduced in CD30(-/-) mice while levels of IFN-gamma, IL-4, IL-5 and IgE in bronchoalveolar lavage fluid, lung tissue and serum were comparable to w.t. mice. Peribronchial lymph node cells from CD30(-/-) mice, re-stimulated in vitro with OVA, secreted significantly lower levels of IL-13 than those from w.t. mice, but showed normal proliferative response and other cytokine production. Exogenous IL-13 reconstituted airway recruitment of leukocytes in OVA-challenged CD3O(-/-) mice. Adoptive transfer to naive w.t. mice of in vitro OVA-re-stimulated spleen cells from CD30(-/-) mice failed to induce eosinophilic pulmonary inflammation in contrast to transfer of primed cells from w.t. mice. These results indicate that CD30 is a regulator of T(h)2 responses in the effector-memory phase and a regulator of IL-13 production in memory cells in the lung.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18089617     DOI: 10.1093/intimm/dxm130

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  4 in total

1.  Noninvasive Trafficking of Brentuximab Vedotin and PET Imaging of CD30 in Lung Cancer Murine Models.

Authors:  Lei Kang; Dawei Jiang; Emily B Ehlerding; Todd E Barnhart; Dalong Ni; Jonathan W Engle; Rongfu Wang; Peng Huang; Xiaojie Xu; Weibo Cai
Journal:  Mol Pharm       Date:  2018-03-20       Impact factor: 4.939

2.  Association of a novel functional promoter variant (rs2075533 C>T) in the apoptosis gene TNFSF8 with risk of lung cancer--a finding from Texas lung cancer genome-wide association study.

Authors:  Sheng Wei; Jiangong Niu; Hui Zhao; Zhensheng Liu; Li-E Wang; Younghun Han; Wei V Chen; Christopher I Amos; Thorunn Rafnar; Patrick Sulem; Kari Stefansson; Maria T Landi; Neil E Caporaso; Demetrius Albanes; Michael J Thun; James D McKay; Paul Brennan; Yufei Wang; Richard S Houlston; Margaret R Spitz; Qingyi Wei
Journal:  Carcinogenesis       Date:  2011-02-02       Impact factor: 4.944

Review 3.  CD30: from basic research to cancer therapy.

Authors:  Hiromi Muta; Eckhard R Podack
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

4.  Combination blockade of OX40L and CD30L inhibits allergen-driven memory TH2 cell reactivity and lung inflammation.

Authors:  Donald T Gracias; Gurupreet S Sethi; Amit K Mehta; Haruka Miki; Rinkesh K Gupta; Hideo Yagita; Michael Croft
Journal:  J Allergy Clin Immunol       Date:  2020-11-05       Impact factor: 14.290

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.